Self-administered high-flow therapy in advanced chronic obstructive pulmonary disease or chronic type 1 respiratory failure : extract / Institute for Quality and Efficiency in Health Care (IQWiG)
RESEARCH QUESTION: This study aims to assess the benefit of self-administered high-flow therapy (HFT) in comparison with standard treatment without HFT in patients with stable, advanced chronic obstructive pulmonary disease (COPD) or in patients with chronic respiratory failure (CRF) type 1 with regard to patient-relevant outcomes. Self-administration is suitable for the home environment, at nursing facilities, at rehabilitation clinics, or at facilities of statutory health insurance physicians. CONCLUSION: On the basis of 1 study on HFT in COPD associated with CRF type 1, no hint of any greater benefit or harm of oxygen administration via HFT in comparison with oxygen administration via mask was found when administered repeatedly during physical exercise. It remains unclear whether a comparable benefit might be present. Data from 1 study on the long-term use of HFT were unusable because only a subgroup of patients suffered from CRF type 1 and therefore received an appropriate comparator therapy. For the application of HFT in comparison with oxygen administration alone in patients with CRF type 1 and an underlying disease other than COPD, 1 study with repeated application during exercise was found. The data were unusable for a benefit assessment. Regarding the use of HFT in patients with COPD and CRF type 2, usable data were available from 1 included study. This study revealed no benefit or harm of HFT in comparison with noninvasive ventilation. Since the data of the study are difficult to interpret, it remains unclear whether a comparable benefit exists. For COPD without CRF symptoms, data were available from only 1 study and unsuitable for a benefit assessment. Across indications, the data do not suggest any harm of HFT. For all 4 indications, both completed and ongoing randomized controlled trials (RCTs) were found for assessing HFT. From the described results of all included studies - i.e., with additional consideration of the studies not usable for the benefit assessment - it follows that the HFT method to be assessed has the potential of a required treatment alternative. Testing in initially 2 studies is deemed feasible and meaningful..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
6 July 2021 |
|---|---|
| Erschienen: |
Köln, Germany: Institute for Quality and Efficiency in Health Care (IQWiG) ; 6 July 2021 |
| Ausgabe: |
Version 1.1. |
| Sprache: |
Englisch |
|---|
| WorkTitle: |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Oxygen Inhalation Therapy |
|---|
| Anmerkungen: |
Translation of Chapters 1 to 6 of the final report N20-02 High-Flow-Therapie zur Selbstanwendung bei fortgeschrittener chronisch obstruktiver Lungenerkrankung oder chronischer respiratorischer Insuffizienz Typ 1 (Version N20-02; Status: 6 July 2021 [German original], 23 August 2021 [English translation]). - Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed April 30, 2022 ) |
|---|
| Umfang: |
1 online resource (1 PDF file (vi, 31 pages)) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
180625512X |
|---|
| LEADER | 01000nam a22002652 4500 | ||
|---|---|---|---|
| 001 | 180625512X | ||
| 003 | DE-627 | ||
| 005 | 20220608125758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220608s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)180625512X | ||
| 035 | |a (DE-599)KEP078645425 | ||
| 035 | |a (OCoLC)1327585840 | ||
| 035 | |a (NCBI)9918282178606676 | ||
| 035 | |a (EBP)078645425 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 110 | 2 | |a Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, |e verfasserin |4 aut | |
| 240 | 1 | 0 | |a High-Flow-Therapie zur Selbstanwendung bei fortgeschrittener chronisch obstruktiver Lungenerkrankung oder chronischer respiratorischer Insuffizienz Typ 1 |
| 245 | 1 | 0 | |a Self-administered high-flow therapy in advanced chronic obstructive pulmonary disease or chronic type 1 respiratory failure |b extract |c Institute for Quality and Efficiency in Health Care (IQWiG) |
| 250 | |a Version 1.1. | ||
| 264 | 1 | |a Köln, Germany |b Institute for Quality and Efficiency in Health Care (IQWiG) |c 6 July 2021 | |
| 300 | |a 1 online resource (1 PDF file (vi, 31 pages)) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Translation of Chapters 1 to 6 of the final report N20-02 High-Flow-Therapie zur Selbstanwendung bei fortgeschrittener chronisch obstruktiver Lungenerkrankung oder chronischer respiratorischer Insuffizienz Typ 1 (Version N20-02; Status: 6 July 2021 [German original], 23 August 2021 [English translation]). - Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed April 30, 2022 ) | ||
| 520 | |a RESEARCH QUESTION: This study aims to assess the benefit of self-administered high-flow therapy (HFT) in comparison with standard treatment without HFT in patients with stable, advanced chronic obstructive pulmonary disease (COPD) or in patients with chronic respiratory failure (CRF) type 1 with regard to patient-relevant outcomes. Self-administration is suitable for the home environment, at nursing facilities, at rehabilitation clinics, or at facilities of statutory health insurance physicians. CONCLUSION: On the basis of 1 study on HFT in COPD associated with CRF type 1, no hint of any greater benefit or harm of oxygen administration via HFT in comparison with oxygen administration via mask was found when administered repeatedly during physical exercise. It remains unclear whether a comparable benefit might be present. Data from 1 study on the long-term use of HFT were unusable because only a subgroup of patients suffered from CRF type 1 and therefore received an appropriate comparator therapy. For the application of HFT in comparison with oxygen administration alone in patients with CRF type 1 and an underlying disease other than COPD, 1 study with repeated application during exercise was found. The data were unusable for a benefit assessment. Regarding the use of HFT in patients with COPD and CRF type 2, usable data were available from 1 included study. This study revealed no benefit or harm of HFT in comparison with noninvasive ventilation. Since the data of the study are difficult to interpret, it remains unclear whether a comparable benefit exists. For COPD without CRF symptoms, data were available from only 1 study and unsuitable for a benefit assessment. Across indications, the data do not suggest any harm of HFT. For all 4 indications, both completed and ongoing randomized controlled trials (RCTs) were found for assessing HFT. From the described results of all included studies - i.e., with additional consideration of the studies not usable for the benefit assessment - it follows that the HFT method to be assessed has the potential of a required treatment alternative. Testing in initially 2 studies is deemed feasible and meaningful. | ||
| 650 | 2 | |a Pulmonary Disease, Chronic Obstructive |x therapy | |
| 650 | 2 | |a Respiratory Insufficiency |x therapy | |
| 650 | 2 | |a Oxygen Inhalation Therapy |x methods | |
| 655 | 2 | |a Systematic Review | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK573807/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 4145316118 |h h64 NCBI |y zi06404 |z 08-06-22 | ||
| 980 | |2 40 |1 01 |x 0007 |b 4145311884 |h OLR-NCB-BOOKSHELF |y xsn |z 08-06-22 | ||
| 980 | |2 74 |1 01 |x 0354 |b 4145305876 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-06-22 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 414504889X |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 08-06-22 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 4145049519 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 08-06-22 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 4145049527 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 08-06-22 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK573807/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK573807/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK573807/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK573807/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK573807/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||